SpaceFOMO
SpaceFOMO
All Tags
topic

Biotechnology

1 company 1 moments 7 signals

Moments

Success 72 FOMO
BioOrbit completes six-week ISS protein-crystallisation experiment

BioOrbit completed a six-week experiment aboard the International Space Station to produce protein crystals in microgravity. The company used a specially developed manufacturing unit to grow crystals that could enable highly concentrated cancer medicines suitable for subcutaneous injection rather than intravenous infusion. UKRI announced the successful completion on October 23, 2026, describing it as an important step toward commercial pharmaceutical manufacturing in space.

Oct 28, 2026
Success 72 FOMO
BioOrbit completes six-week ISS protein-crystallisation experiment

BioOrbit completed a six-week experiment aboard the International Space Station to produce protein crystals in microgravity. The company used a specially developed manufacturing unit to grow crystals that could enable highly concentrated cancer medicines suitable for subcutaneous injection rather than intravenous infusion. UKRI announced the successful completion on October 23, 2026, describing it as an important step toward commercial pharmaceutical manufacturing in space.

Oct 28, 2026
Success 83 FOMO
BioOrbit raises £9.8 million seed round

BioOrbit raised £9.8 million ($13.2 million) in seed funding, described by the BioIndustry Association as the world's largest seed round for in-space manufacturing. The round was co-led by LocalGlobe and Breega, with support from Auxxo, Seedcamp, Type One, 7 percent, and angel investors. The funding will accelerate BioOrbit's BOX autonomous manufacturing unit and its move toward contracted pharmaceutical programmes.

Apr 30, 2026
Success 83 FOMO
BioOrbit raises £9.8 million seed round

BioOrbit raised £9.8 million ($13.2 million) in seed funding, described by the BioIndustry Association as the world's largest seed round for in-space manufacturing. The round was co-led by LocalGlobe and Breega, with support from Auxxo, Seedcamp, Type One, 7 percent, and angel investors. The funding will accelerate BioOrbit's BOX autonomous manufacturing unit and its move toward contracted pharmaceutical programmes.

Apr 30, 2026
Live 46 FOMO
BioOrbit receives £250,000 UK Space Agency feasibility study

The UK Space Agency provided funding for a £250,000 feasibility study to develop a scalable in-orbit manufacturing system for crystallising biologic drugs used in cancer treatment. The study, funded through the Unlocking Space Portfolio, involves BioOrbit, the MHRA, and the UK Space Agency. It runs until March 2026 and is intended to clarify whether existing terrestrial pharmaceutical regulations apply to in-orbit manufacturing for patient use.

Mar 5, 2026
Live 46 FOMO
BioOrbit receives £250,000 UK Space Agency feasibility study

The UK Space Agency provided funding for a £250,000 feasibility study to develop a scalable in-orbit manufacturing system for crystallising biologic drugs used in cancer treatment. The study, funded through the Unlocking Space Portfolio, involves BioOrbit, the MHRA, and the UK Space Agency. It runs until March 2026 and is intended to clarify whether existing terrestrial pharmaceutical regulations apply to in-orbit manufacturing for patient use.

Mar 5, 2026
Announced 19 FOMO
Astron signs Helogen for three biolab-satellite launch missions

Astron Systems announced Helogen as a customer under an agreement for three missions to launch biolab satellites on Astron's fully reusable small rocket. The announcement did not disclose contract value, launch dates, or payload masses. It adds a commercial customer to Astron's emerging launch manifest.

Nov 27, 2025

Get this topic in your inbox

A weekly digest of the moments you'd regret missing. Starting soon: get on the list.